Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK R1192P||malignant pheochromocytoma||predicted - sensitive||ALK Inhibitor||Brigatinib||Case Reports/Case Series||Actionable||In a clinical case study, Alunbrig (brigatinib) treatment resulted in a partial response (PR) after 2 months of therapy and a sustained PR at 10 months in a patient with malignant pheochromocytoma harboring ALK R1192P (PMID: 34371380).||34371380|
|ALK R1192P||malignant pheochromocytoma||no benefit||ALK Inhibitor||Alectinib + Octreotide||Case Reports/Case Series||Actionable||In a clinical case study, addition of Alecensa (alectinib) to Octreotide treatment did not lead to a response in a patient with malignant pheochromocytoma harboring ALK R1192P, with a radiological stable disease after 1 month of treatment and disease progression after 5 months of treatment (PMID: 34371380).||34371380|
|ALK R1192P||Advanced Solid Tumor||sensitive||ALK Inhibitor||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).||27049722|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|